Urticaria and Angioedema

Key Points

• Urticaria is a Type I hypersensitivity reaction with pruritic wheal formation from mediator-driven vasodilation and capillary leak.
• Angioedema involves deeper skin/submucosal swelling and can occur with or without visible hives.
• Triggers include foods, medications, insect stings, infections, latex, physical stimuli, and environmental allergens.
• Airway-risk symptoms (throat swelling, dysphagia, dyspnea, wheeze) require immediate escalation.
• Chronic urticaria is generally defined by symptoms persisting longer than 6 weeks.

Pathophysiology

Urticaria develops when mast cells and basophils release mediators that increase capillary and venous vasodilation, producing edematous wheals and pruritus. Reactions may be immune-mediated (including IgE receptor-linked pathways) or nonimmune-mediated through physical, emotional, or medication-related mast-cell activation. Wheals are often red-pink and can appear rapidly, with symptom courses ranging from transient to persistent.

Angioedema is characterized by deeper dermal or submucosal swelling and commonly involves the face, hands, feet, genitalia, or throat. It can affect gastrointestinal, bronchial, and laryngeal mucosa and may occur with or without urticaria. Swelling can begin abruptly or evolve over 1-2 hours; most reactions improve over days, though recurrence can occur.

Classification

• Immune-mediated urticaria: IgE-linked mast-cell/basophil activation in Type I hypersensitivity pathways.
• Autoimmune-linked urticaria: IgE-receptor-directed signaling that triggers mast-cell degranulation.
• Nonimmune-mediated urticaria: Medication, physical, or emotional stimuli that activate mediator release without classic IgE allergen pathways.
• Cold urticaria subtype: Triggered by cold exposure (water, objects, weather); may be acquired or familial.
• Histamine-mediated angioedema: More common pathway linked to mast-cell/basophil activation and increased vascular permeability.
• Bradykinin-mediated angioedema: Linked to hereditary/acquired C1-inhibitor pathway abnormalities or medication-associated pathways (for example ACE inhibitor exposure).

Nursing Assessment

NCLEX Focus

Prioritize airway and perfusion cues before skin-only findings when angioedema is present or suspected.

• Assess trigger exposure history, onset timing, and recurrence pattern.
• Assess wheal characteristics (distribution, color, size, edema, pruritus, frequency, duration), including mucosal involvement.
• Screen for angioedema in face/lips/tongue/throat/hands/feet and for respiratory compromise.
• Assess severity cues including tachypnea, heart-rate change, wheeze, fever, fatigue, GI symptoms, and systemic progression.
• Distinguish acute from chronic timeline (greater than 6 weeks suggests chronic pathway).
• Include focused multisystem exam when severity is unclear (head/neck/oropharynx, abdominal findings, neurologic findings, musculoskeletal inflammation, and full skin survey).
• For persistent nonhealing wheals, anticipate biopsy evaluation to rule out urticarial vasculitis.
• Review diagnostic context for CBC, liver chemistries, thyroid-stimulating hormone, and targeted kidney/liver/thyroid follow-up when abnormalities are present.
• For suspected cold urticaria, understand confirmation context (ice-cube forearm provocation with localized wheal response) and inflammatory lab trends (for example CRP/ESR/leukocyte changes).
• In unclear angioedema etiology, anticipate complement-focused workup including C1-inhibitor and C4 levels.

Nursing Interventions

• Remove or avoid suspected triggers and escalate severe or rapidly progressive reactions.
• Maintain readiness for emergency response when airway symptoms or systemic instability develops.
• Administer ordered symptomatic therapy and monitor response trend closely.
• Reinforce trigger-reduction strategies (avoid heat, stress, tight clothing, alcohol, and NSAID exposure when these worsen symptoms).
• In cold-urticaria pathways, teach strict cold-stimulus avoidance and acute-warming safety measures.
• For angioedema with unknown cause, stop nonessential medications per provider direction while evaluating potential triggers.
• For severe airway-threat angioedema, prepare for high-acuity airway interventions (including possible surgical airway pathway when ordered).
• Teach that hives/angioedema can progress to anaphylaxis and that post-epinephrine emergency evaluation is still required.
• Reinforce teaching on trigger avoidance, recurrence precautions, and urgent return criteria.

Airway Threat

Angioedema involving the tongue, oropharynx, or larynx can deteriorate rapidly and should be treated as an airway emergency.

Pharmacology

Drug Class	Examples	Key Nursing Considerations
antihistamines	Diphenhydramine, cetirizine, loratadine	First-line symptom control for pruritus and wheal burden; monitor sedation and response.
corticosteroids	Systemic and topical corticosteroid pathways	Used in selected severe inflammatory reactions; monitor infection and adverse-effect risk.
hypersensitivity-types-and-anaphylaxis-response (epinephrine)	IM epinephrine	Reserve for severe systemic reaction or evolving anaphylaxis with airway/circulatory compromise.
ace-inhibitors	Class-based agents	Screen for ACE inhibitor-associated angioedema and discontinue suspected culprit medication urgently if airway risk is present.
Plasma/C1 inhibitor rescue pathways	Fresh frozen plasma, C1 inhibitor concentrate	Consider in selected ACE inhibitor-associated angioedema pathways per provider protocol.

Clinical Judgment Application

Clinical Scenario

A patient develops diffuse itchy wheals and progressive lip swelling shortly after a new medication exposure.

• Recognize Cues: New urticaria with evolving angioedema and recent trigger exposure.
• Analyze Cues: Pattern suggests acute hypersensitivity with airway-risk potential.
• Prioritize Hypotheses: Priority is preventing airway compromise and systemic deterioration.
• Generate Solutions: Stop exposure, activate urgent assessment pathway, and prepare emergency medications.
• Take Action: Implement ordered treatment and continuous monitoring of airway, breathing, and hemodynamics.
• Evaluate Outcomes: Swelling and wheals regress without progression to respiratory compromise.

Related Concepts

• hypersensitivity-types-and-anaphylaxis-response - Immune mechanisms and escalation framework.
• anaphylaxis - High-acuity severe reaction pathway.
• antihistamines - Primary symptomatic pharmacologic support.
• allergic-rhinitis - Common atopy-linked comorbidity.
• infectious-and-inflammatory-skin-conditions - Differential assessment for inflammatory skin findings.

Self-Check

1. Which findings distinguish skin-limited urticaria from airway-threatening angioedema?
2. Why can urticaria be present in both immune-mediated and nonimmune-mediated pathways?
3. What immediate actions are required when throat swelling accompanies hives?